Multiple myeloma
- Use multidrug induction built from proteasome/IMiD/antibody classes
- Transplant eligibility shapes initial strategy
- Autologous stem-cell transplant remains important for fit patients
- Maintenance therapy prolongs remission
- Relapse therapy follows prior exposure + cytogenetic risk
- Bone, kidney, infection + thrombosis supportive care is essential
Use at a glance
- Use multidrug induction built from proteasome/IMiD/antibody classes
Escalation / refractory disease
- Transplant eligibility shapes initial strategy
- Maintenance therapy prolongs remission
Later-line options
- Autologous stem-cell transplant remains important for fit patients
Monitoring / follow-up
- Relapse therapy follows prior exposure + cytogenetic risk
- Bone, kidney, infection + thrombosis supportive care is essential
Self-check
- What drug classes form myeloma induction?
Multidrug induction built from proteasome/IMiD/antibody classes. - What shapes initial myeloma strategy?
Transplant eligibility.
Drugs used for this (3)
All clinical uses · Open Multiple myeloma in the interactive console ↗